Charles Peloquin, Pharm.D.
Professor And The Jack C. Massey Professor; Division Head, Translational Research
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6266
Business Email:
peloquin@ufl.edu
About Charles Peloquin
Prior to coming to the University of Florida, Dr. Peloquin completed a hospital pharmacy residency at Duke University Medical Center, where he also served on the clinical staff. He also completed a fellowship in Infectious Diseases and Pharmacokinetics at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y. For 20 years, Dr. Peloquin was the Director of the Infectious Disease Pharmacokinetics Laboratory (IDPL) at National Jewish Health, Denver, CO. He now serves as Professor of Pharmacy and Medicine at UF, where the IDPL now is located. Dr. Peloquin and his lab are part of the UF Emerging Pathogens Institute. He has served a consultant to the FDA, CDC and WHO, and has contributed to national guidelines on the treatment tuberculosis and the treatment of opportunistic infections in patients living with AIDS.
Accomplishments
Lifetime Achievement Award
2023
·
The North American Region of the International Union against Tuberculosis and Lung Disease
Member
2004-Current
·
International Society of Antimicrobial Pharmacology
Member
1991-Current
·
Society of Infectious Disease Pharmacists
Member
1990-Current
·
American Society of Microbiology
Member
1986-Current
·
American College of Clinical Pharmacy
Teaching Profile
Courses Taught
2013-2021
PHA7979 Advanced Research
2013-2021
PHA7980 Research for Doctoral Dissertation
2012,2018
PHA6935 Selected Topics in Pharmacy
2018
PHA6971 Research for Master’s Thesis
2017-2018
PHA6910 Supervised Research
2014-2018,2021-2022
PHA6938 Research Seminar
2016-2017
PHA5878C Pt Care 3: Cv and Pulm
2012-2014
PHA5783 Pharmacotherapy 3
2014
PHA5787 Pharmacotherapy 5
2011,2013
PHA5907 Research in Phar Prac
2012
PHA5113 Personalized Medicine
2012
PHA6125 Pharmacokinetics and Biopharmaceutics
2011
PHA5113C Thera Mon/Pharmacogen
2010
PHA4907 Probs in Pharm Prac
2021-2023
PHA5876C Pt Care 8 Complex Pts
Research Profile
Dr. Peloquin’s laboratory serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, anti-HIV drugs, and antibacterial drugs including beta-lactams and linezolid. His research efforts focus on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.
Open Researcher and Contributor ID (ORCID)
0000-0001-9002-7052
Publications
2023
Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
27(5):401-407
[DOI] 10.5588/ijtld.22.0591.
[PMID] 37143230.
2023
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections
International Journal of Antimicrobial Agents.
61(3)
[DOI] 10.1016/j.ijantimicag.2023.106727.
2023
Concomitant Treatment of TB and HCV in Coinfected Patients Using Serum Drug Concentration Monitoring
Open Forum Infectious Diseases.
[DOI] 10.1093/ofid/ofad237.
2023
Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
Journal of burn care & research : official publication of the American Burn Association.
44(1):121-128
[DOI] 10.1093/jbcr/irac099.
[PMID] 35896122.
2023
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
The European respiratory journal.
61(3)
[DOI] 10.1183/13993003.01596-2022.
[PMID] 36328357.
2023
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
76(3):497-505
[DOI] 10.1093/cid/ciac511.
[PMID] 35731948.
2023
Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg.
AIDS (London, England).
[DOI] 10.1097/QAD.0000000000003576.
[PMID] 37070558.
2023
Pretomanid-resistant tuberculosis.
The Journal of infection.
86(5):520-524
[DOI] 10.1016/j.jinf.2023.01.039.
[PMID] 36738862.
2023
Reply to Upton, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[DOI] 10.1093/cid/ciad188.
[PMID] 36978221.
2023
Rifampin urinary excretion to predict serum targets in children with tuberculosis: a prospective diagnostic accuracy study.
Archives of disease in childhood.
[DOI] 10.1136/archdischild-2022-325250.
[PMID] 37171408.
2023
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
27(2):135-139
[DOI] 10.5588/ijtld.22.0448.
[PMID] 36853114.
2023
Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function
Respiratory Medicine.
212
[DOI] 10.1016/j.rmed.2023.107237.
2023
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Pharmacotherapy.
43(1):6-14
[DOI] 10.1002/phar.2744.
[PMID] 36401796.
2022
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis
Journal of Cystic Fibrosis.
21(2):348-352
[DOI] 10.1016/j.jcf.2021.08.010.
2022
Another trial for the TARGET trial.
Intensive care medicine.
48(6):774-775
[DOI] 10.1007/s00134-022-06654-9.
[PMID] 35230463.
2022
Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy
Antimicrobial Agents and Chemotherapy.
66(1)
[DOI] 10.1128/aac.01611-21.
2022
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics
Antimicrobial Agents and Chemotherapy.
66(2)
[DOI] 10.1128/aac.02046-21.
[PMID] 34902271.
2022
Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis.
Frontiers in pharmacology.
13
[DOI] 10.3389/fphar.2022.1048653.
[PMID] 36578553.
2022
Clinical standards for the dosing and management of TB drugs.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
26(6):483-499
[DOI] 10.5588/ijtld.22.0188.
[PMID] 35650702.
2022
Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype
Antimicrobial Agents and Chemotherapy.
66(10)
[DOI] 10.1128/aac.00695-22.
[PMID] 36165631.
2022
Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
75(4):682-689
[DOI] 10.1093/cid/ciab992.
[PMID] 34849645.
2022
Determining in vitro and ex vivo protein binding of levofloxacin and moxifloxacin in patients with TB.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
26(12):1177-1179
[DOI] 10.5588/ijtld.22.0278.
[PMID] 36447318.
2022
Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies.
Nature communications.
13(1)
[DOI] 10.1038/s41467-022-35730-3.
[PMID] 36581633.
2022
Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol.
Neurological research and practice.
4(1)
[DOI] 10.1186/s42466-022-00168-x.
[PMID] 35067230.
2022
Effect of Rifabutin in Dolutegravir Dosing: A Case Series.
Journal of the International Association of Providers of AIDS Care.
21
[DOI] 10.1177/23259582221111077.
[PMID] 36026587.
2022
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
The Lancet. Microbe.
3(6):e408-e416
[DOI] 10.1016/S2666-5247(21)00308-6.
[PMID] 35659902.
2022
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid
International Journal of Antimicrobial Agents.
59(2)
[DOI] 10.1016/j.ijantimicag.2021.106509.
2022
High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis
Journal of Clinical Investigation.
132(6)
[DOI] 10.1172/jci155851.
2022
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
79(18):1586-1591
[DOI] 10.1093/ajhp/zxac171.
[PMID] 35704702.
2022
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
Journal of Clinical Investigation.
132(18)
[DOI] 10.1172/jci161564.
2022
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy.
66(9)
[DOI] 10.1128/aac.00408-22.
[PMID] 35916515.
2022
Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue
Antimicrobial Agents and Chemotherapy.
66(8)
[DOI] 10.1128/aac.00438-22.
[PMID] 35862739.
2022
Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
Tuberculosis (Edinburgh, Scotland).
136
[DOI] 10.1016/j.tube.2022.102246.
[PMID] 35961094.
2022
Practices of therapeutic drug monitoring in tuberculosis: an international survey.
The European respiratory journal.
59(4)
[DOI] 10.1183/13993003.02787-2021.
[PMID] 35086830.
2022
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia
Antimicrobial Agents and Chemotherapy.
66(7)
[DOI] 10.1128/aac.00563-22.
[PMID] 35699444.
2021
Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.
Antibiotics (Basel, Switzerland).
10(10)
[DOI] 10.3390/antibiotics10101154.
[PMID] 34680734.
2021
Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase
Antimicrobial Agents and Chemotherapy.
65(10)
[DOI] 10.1128/aac.00693-21.
2021
Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy
Antimicrobial Agents and Chemotherapy.
65(6)
[DOI] 10.1128/aac.00144-21.
2021
Comment on: The case for ‘conservative pharmacotherapy’.
The Journal of antimicrobial chemotherapy.
76(7):1951-1952
[DOI] 10.1093/jac/dkab087.
[PMID] 33851696.
2021
Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment.
Journal of the Pediatric Infectious Diseases Society.
10(2):104-111
[DOI] 10.1093/jpids/piaa024.
[PMID] 32170944.
2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression
Antimicrobial Agents and Chemotherapy.
65(4)
[DOI] 10.1128/aac.02533-20.
2021
Dynamic PET-facilitated modeling and high-dose rifampin regimens for
Staphylococcus aureus
orthopedic implant–associated infections
Science Translational Medicine.
13(622)
[DOI] 10.1126/scitranslmed.abl6851.
[PMID] 34851697.
2021
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
25(1):36-42
[DOI] 10.5588/ijtld.20.0301.
[PMID] 33384043.
2021
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
Emerging infectious diseases.
27(1):332-4
[DOI] 10.3201/eid2701.203766.
[PMID] 33227229.
2021
Optimising pyrazinamide for the treatment of tuberculosis.
The European respiratory journal.
58(1)
[DOI] 10.1183/13993003.02013-2020.
[PMID] 33542052.
2021
Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
92
[DOI] 10.1016/j.meegid.2021.104856.
[PMID] 33839311.
2021
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
The Journal of antimicrobial chemotherapy.
76(4):1019-1024
[DOI] 10.1093/jac/dkaa550.
[PMID] 33378452.
2021
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.
Clinical pharmacokinetics.
60(6):685-710
[DOI] 10.1007/s40262-021-00997-0.
[PMID] 33674941.
2021
Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness.
Antibiotics (Basel, Switzerland).
10(6)
[DOI] 10.3390/antibiotics10060739.
[PMID] 34207312.
2021
Reply to: Observations on malnutrition and anti-TB drugs in Ghana.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
25(9):779-780
[DOI] 10.5588/ijtld.21.0357.
[PMID] 34802507.
2021
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens
Antimicrobial Agents and Chemotherapy.
65(2)
[DOI] 10.1128/aac.02172-20.
2021
The Treatment of Tuberculosis.
Clinical pharmacology and therapeutics.
110(6):1455-1466
[DOI] 10.1002/cpt.2261.
[PMID] 33837535.
2021
Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.
Clinical pharmacokinetics.
60(6):711-725
[DOI] 10.1007/s40262-021-01000-6.
[PMID] 33751415.
2021
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems.
Expert opinion on drug metabolism & toxicology.
17(1):23-39
[DOI] 10.1080/17425255.2021.1836158.
[PMID] 33040625.
2021
Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets
Journal of Infection and Chemotherapy.
27(6):929-930
[DOI] 10.1016/j.jiac.2021.02.020.
2020
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis
Clinical Therapeutics.
42(11):e220-e241
[DOI] 10.1016/j.clinthera.2020.09.009.
2020
Building Optimal Three-Drug Combination Chemotherapy Regimens
Antimicrobial Agents and Chemotherapy.
64(11)
[DOI] 10.1128/aac.01610-20.
2020
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
71(9):2336-2344
[DOI] 10.1093/cid/ciz1107.
[PMID] 31712809.
2020
Comment on “Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples”.
Therapeutic drug monitoring.
42(6)
[DOI] 10.1097/FTD.0000000000000810.
[PMID] 33197165.
2020
Correction for Kempker et al., “A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment”.
Antimicrobial agents and chemotherapy.
64(2)
[DOI] 10.1128/AAC.02358-19.
[PMID] 31988109.
2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial Agents and Chemotherapy.
64(12)
[DOI] 10.1128/aac.01376-20.
2020
Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
Nature medicine.
26(4):529-534
[DOI] 10.1038/s41591-020-0770-2.
[PMID] 32066976.
2020
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.
The Journal of antimicrobial chemotherapy.
75(12):3644-3651
[DOI] 10.1093/jac/dkaa359.
[PMID] 32910809.
2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy.
64(9)
[DOI] 10.1128/aac.00713-20.
2020
Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
International journal of antimicrobial agents.
55(2)
[DOI] 10.1016/j.ijantimicag.2019.10.021.
[PMID] 31704214.
2020
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
26(8):1008-1016
[DOI] 10.1016/j.cmi.2020.03.008.
[PMID] 32205294.
2020
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
70(8):1774-1780
[DOI] 10.1093/cid/ciz942.
[PMID] 31560376.
2020
Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
American journal of respiratory and critical care medicine.
201(4):469-477
[DOI] 10.1164/rccm.201903-0646OC.
[PMID] 31647877.
2020
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
American journal of respiratory and critical care medicine.
201(3):313-324
[DOI] 10.1164/rccm.201905-0990OC.
[PMID] 31613648.
2020
Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.
Therapeutic drug monitoring.
42(1):129-132
[DOI] 10.1097/FTD.0000000000000675.
[PMID] 31318843.
2020
Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
Clinical pharmacokinetics.
59(7):899-910
[DOI] 10.1007/s40262-020-00860-8.
[PMID] 31981103.
2020
Pharmacokinetics of Efavirenz 600Â mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
Clinical therapeutics.
42(9):1818-1825
[DOI] 10.1016/j.clinthera.2020.07.008.
[PMID] 32811669.
2020
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Journal of the Pediatric Infectious Diseases Society.
9(1):14-20
[DOI] 10.1093/jpids/piy106.
[PMID] 30395239.
2020
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
151
[DOI] 10.1016/j.ejps.2020.105421.
[PMID] 32531349.
2020
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing
Antimicrobial Agents and Chemotherapy.
64(9)
[DOI] 10.1128/aac.00745-20.
2020
Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis
Antimicrobial Agents and Chemotherapy.
64(10)
[DOI] 10.1128/aac.01174-20.
2020
Roger W. Jelliffe, M.D. (1929-2020).
Clinical pharmacokinetics.
59(9)
[DOI] 10.1007/s40262-020-00928-5.
[PMID] 32789605.
2020
The Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid Following Intravenous Administration: A Report of Successfully Treated Infant with Mycoplasma hominis Meningitis.
The Pediatric infectious disease journal.
39(8):e183-e184
[DOI] 10.1097/INF.0000000000002655.
[PMID] 32195773.
2020
Variable linezolid exposure and response and the role of therapeutic drug monitoring: Case series
Clinical Case Reports.
8(7):1126-1129
[DOI] 10.1002/ccr3.2835.
[PMID] 32695341.
2019
A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment
Antimicrobial Agents and Chemotherapy.
63(12)
[DOI] 10.1128/aac.01215-19.
2019
Antimycobacterial Drugs
Lippincott’s Illustrated Reviews: Pharmacology.
7th Edition(Wolters Kluwer):413-422
2019
Bacterial Factors and Relapse after Tuberculosis Therapy.
The New England journal of medicine.
380(2)
[DOI] 10.1056/NEJMc1813645.
[PMID] 30628424.
2019
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy.
63(5)
[DOI] 10.1128/aac.00055-19.
2019
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans
Antimicrobial Agents and Chemotherapy.
63(10)
[DOI] 10.1128/aac.00913-19.
2019
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
International journal of antimicrobial agents.
53(3):275-283
[DOI] 10.1016/j.ijantimicag.2018.10.012.
[PMID] 30385322.
2019
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old
Antimicrobial Agents and Chemotherapy.
63(10)
[DOI] 10.1128/aac.00839-19.
2019
Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old
Antimicrobial Agents and Chemotherapy.
63(1)
[DOI] 10.1128/aac.01657-18.
2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Antimicrobial Agents and Chemotherapy.
63(7)
[DOI] 10.1128/aac.00279-19.
2019
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients
Antimicrobial Agents and Chemotherapy.
63(7)
[DOI] 10.1128/aac.00384-19.
2019
Management of patients with multidrug-resistant tuberculosis
˜The œinternational journal of tuberculosis and lung disease (Online).
23(6):645-662
2019
Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy.
63(5)
[DOI] 10.1128/aac.02569-18.
2019
Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
The Journal of antimicrobial chemotherapy.
74(9):2698-2706
[DOI] 10.1093/jac/dkz238.
[PMID] 31243456.
2019
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
American journal of respiratory and critical care medicine.
199(9):1167-1168
[DOI] 10.1164/rccm.201812-2281LE.
[PMID] 30645140.
2019
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine.
200(10):e93-e142
[DOI] 10.1164/rccm.201909-1874st.
2019
Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial
PLOS Medicine.
16(10)
[DOI] 10.1371/journal.pmed.1002891.
[PMID] 31584944.
2018
A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
The European respiratory journal.
51(2)
[DOI] 10.1183/13993003.02166-2017.
[PMID] 29437945.
2018
A PRELIMINARY ANALYSIS OF PROLONGED ABSORPTION RATE OF PONAZURIL IN RED-FOOTED TORTOISES, CHELONOIDIS CARBONARIA.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.
49(3):802-805
[DOI] 10.1638/2017-0178.1.
[PMID] 30212324.
2018
Activity of Moxifloxacin against
Mycobacterium tuberculosis
in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model
Antimicrobial Agents and Chemotherapy.
62(12)
[DOI] 10.1128/aac.01470-18.
2018
Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.
Clinical pharmacology and therapeutics.
103(3):502-510
[DOI] 10.1002/cpt.760.
[PMID] 28597911.
2018
Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.
Antimicrobial agents and chemotherapy.
62(3)
[DOI] 10.1128/AAC.02099-17.
[PMID] 29263072.
2018
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
American journal of respiratory and critical care medicine.
198(5):657-666
[DOI] 10.1164/rccm.201712-2524OC.
[PMID] 29954183.
2018
Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
Antimicrobial agents and chemotherapy.
62(5)
[DOI] 10.1128/AAC.01802-17.
[PMID] 29463526.
2018
Erratum for Alsultan et al., “Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis”.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.02229-17.
[PMID] 29269434.
2018
Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.
The Pediatric infectious disease journal.
37(1):43-51
[DOI] 10.1097/INF.0000000000001687.
[PMID] 28719501.
2018
Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations
Antimicrobial Agents and Chemotherapy.
62(9)
[DOI] 10.1128/aac.00008-18.
2018
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Antimicrobial Agents and Chemotherapy.
62(10)
[DOI] 10.1128/aac.00770-18.
2018
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium Tuberculosis in a Hollow-Fiber Infection Model
Antimicrobial Agents and Chemotherapy.
62(8)
[DOI] 10.1128/AAC.00221-18;e00221-18.
2018
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model
Antimicrobial Agents and Chemotherapy.
62(8)
[DOI] 10.1128/aac.00221-18.
2018
Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
22(1)
[DOI] 10.5588/ijtld.17.0632.
[PMID] 29297417.
2018
Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.
The Journal of antimicrobial chemotherapy.
73(2):477-483
[DOI] 10.1093/jac/dkx421.
[PMID] 29186509.
2018
Mycobacterium Tuberculosis Strains H37Ra and H37Rv Have Equivalent Minimum Inhibitory Concentrations to Most Antituberculosis Drugs
International Journal of Mycobacteriology.
7(2):156-161
[DOI] 10.4103/ijmy.ijmy\_33\_18.
2018
Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs.
International journal of mycobacteriology.
7(2):156-161
[DOI] 10.4103/ijmy.ijmy_33_18.
[PMID] 29900893.
2018
Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.
Science translational medicine.
10(470)
[DOI] 10.1126/scitranslmed.aau0965.
[PMID] 30518610.
2018
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.
Journal of internal medicine.
[DOI] 10.1111/joim.12780.
[PMID] 29806961.
2018
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.
The Journal of antimicrobial chemotherapy.
73(9):2305-2313
[DOI] 10.1093/jac/dky152.
[PMID] 29701775.
2018
Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.
The European respiratory journal.
51(5)
[DOI] 10.1183/13993003.00109-2018.
[PMID] 29599189.
2018
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients
Antimicrobial Agents and Chemotherapy.
62(12)
[DOI] 10.1128/aac.01092-18.
2018
Protein Binding of First-Line Antituberculosis Drugs
Antimicrobial Agents and Chemotherapy.
62(7)
[DOI] 10.1128/aac.00641-18.
2018
Reply to Chang et al., “Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?”.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.01937-17.
[PMID] 29269429.
2018
Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.
Microbiology insights.
11
[DOI] 10.1177/1178636118804549.
[PMID] 30349291.
2018
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.01692-17.
[PMID] 29038265.
2017
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Trials.
18(1)
[DOI] 10.1186/s13063-017-2292-x.
[PMID] 29178937.
2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
Clinical pharmacology and therapeutics.
102(2):321-331
[DOI] 10.1002/cpt.634.
[PMID] 28124478.
2017
Erratum for Peloquin et al., “Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis”.
Antimicrobial agents and chemotherapy.
61(9)
[DOI] 10.1128/AAC.01524-17.
[PMID] 28839086.
2017
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenetics and genomics.
27(5):190-196
[DOI] 10.1097/FPC.0000000000000277.
[PMID] 28306618.
2017
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
Antimicrobial agents and chemotherapy.
61(6)
[DOI] 10.1128/AAC.00226-17.
[PMID] 28373198.
2017
Mycobacterium tuberculosis Infection among Asian Elephants in Captivity.
Emerging infectious diseases.
23(3):513-516
[DOI] 10.3201/eid2303.160726.
[PMID] 28221115.
2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Antimicrobial agents and chemotherapy.
61(8)
[DOI] 10.1128/AAC.00038-17.
[PMID] 28559269.
2017
Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
21(1):121-123
[DOI] 10.5588/ijtld.16.0689.
[PMID] 28157477.
2017
Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Journal of pharmaceutical sciences.
106(1):331-337
[DOI] 10.1016/j.xphs.2016.09.033.
[PMID] 27842973.
2017
Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Antimicrobial agents and chemotherapy.
61(2)
[DOI] 10.1128/AAC.01701-16.
[PMID] 27855070.
2017
Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.
mBio.
8(4)
[DOI] 10.1128/mBio.00540-17.
[PMID] 28743810.
2017
Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
Antimicrobial agents and chemotherapy.
61(10)
[DOI] 10.1128/AAC.01066-17.
[PMID] 28739794.
2017
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
Antimicrobial agents and chemotherapy.
61(6)
[DOI] 10.1128/AAC.02625-16.
[PMID] 28289033.
2017
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
CPT: pharmacometrics & systems pharmacology.
6(9):625-634
[DOI] 10.1002/psp4.12218.
[PMID] 28623849.
2017
Reply to Alffenaar et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
64(1):105-106
[PMID] 27789610.
2017
Reply to Srivastava et al., “pH Conditions under Which Pyrazinamide Works in Humans”.
Antimicrobial agents and chemotherapy.
61(9)
[DOI] 10.1128/AAC.01120-17.
[PMID] 28839080.
2017
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Expert review of clinical pharmacology.
10(10):1027-1036
[DOI] 10.1080/17512433.2017.1366311.
[PMID] 28803492.
2017
Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
65(4):704-705
[DOI] 10.1093/cid/cix434.
[PMID] 28482036.
2017
The pharmacological challenges of treating tuberculosis and HIV coinfections.
Expert review of clinical pharmacology.
10(2):213-223
[DOI] 10.1080/17512433.2017.1259066.
[PMID] 27828731.
2017
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.
Microbiology spectrum.
5(1)
[DOI] 10.1128/microbiolspec.TNMI7-0029-2016.
[PMID] 28084209.
2016
Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
Antimicrobial agents and chemotherapy.
60(11):6591-6599
[DOI] 10.1128/AAC.01163-16.
[PMID] 27550361.
2016
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
BMC infectious diseases.
16(1)
[DOI] 10.1186/s12879-016-1790-x.
[PMID] 27567500.
2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
63(7):853-67
[DOI] 10.1093/cid/ciw566.
[PMID] 27621353.
2016
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.
47(3):868-871
[PMID] 27691967.
2016
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
63(7):e147-e195
[DOI] 10.1093/cid/ciw376.
[PMID] 27516382.
2016
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
The Pediatric infectious disease journal.
35(4):414-21
[DOI] 10.1097/INF.0000000000001022.
[PMID] 26658531.
2016
Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
Journal of the Pediatric Infectious Diseases Society.
5(4):356-365
[PMID] 26407268.
2016
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
The Journal of antimicrobial chemotherapy.
71(5):1330-40
[DOI] 10.1093/jac/dkv470.
[PMID] 26832753.
2016
Rifapentine for the treatment of latent tuberculosis.
Expert review of clinical pharmacology.
9(10):1253-1261
[DOI] 10.1080/17512433.2016.1222270.
[PMID] 27545595.
2016
Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis.
The Journal of antimicrobial chemotherapy.
71(6)
[DOI] 10.1093/jac/dkv507.
[PMID] 26851607.
2016
Tuberculosis therapy for 2016 and beyond.
Expert opinion on pharmacotherapy.
17(14):1859-72
[DOI] 10.1080/14656566.2016.1215428.
[PMID] 27457206.
2016
Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.
BMC infectious diseases.
16
[DOI] 10.1186/s12879-016-1576-1.
[PMID] 27250739.
2016
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.
The Journal of antimicrobial chemotherapy.
71(8):2234-40
[DOI] 10.1093/jac/dkw127.
[PMID] 27121401.
2015
Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
Antimicrobial agents and chemotherapy.
59(6):3149-55
[DOI] 10.1128/AAC.00379-15.
[PMID] 25779583.
2015
Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
Antimicrobial agents and chemotherapy.
59(7):3800-7
[DOI] 10.1128/AAC.00341-15.
[PMID] 25870068.
2015
Medications and monitoring in nontuberculous mycobacteria infections.
Clinics in chest medicine.
36(1):55-66
[DOI] 10.1016/j.ccm.2014.11.001.
[PMID] 25676519.
2015
Optimizing the clinical pharmacology of tuberculosis medications.
Clinical pharmacology and therapeutics.
98(4):387-93
[DOI] 10.1002/cpt.180.
[PMID] 26138226.
2015
Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014.
Tuberculosis and respiratory diseases.
78(2):78-84
[DOI] 10.4046/trd.2015.78.2.78.
[PMID] 25861340.
2015
Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
Journal of veterinary pharmacology and therapeutics.
38(2):137-43
[DOI] 10.1111/jvp.12156.
[PMID] 25236765.
2015
Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature.
BMC infectious diseases.
15
[DOI] 10.1186/s12879-015-1093-7.
[PMID] 26265445.
2015
Voriconazole monitoring in children with invasive fungal infections.
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
20(1):17-23
[DOI] 10.5863/1551-6776-20.1.17.
[PMID] 25859166.
2014
A Cyp2C19 Genotype Guided Dosing Approach for Optimizing Voriconazole in Patients With Ifis.
Pharmacotherapy.
34(10)
2014
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
PloS one.
9(7)
[DOI] 10.1371/journal.pone.0101311.
[PMID] 25003557.
2014
Concomitant Use of Carbamazepine and Rifampin in a Patient With Mycobacterium avium Complex and Seizure Disorder.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.
30(3):93-96
[DOI] 10.1177/8755122514523934.
[PMID] 34860865.
2014
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Pharmacotherapy.
34(7):703-18
[DOI] 10.1002/phar.1400.
[PMID] 24510446.
2014
Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Pharmacotherapy.
34(3):265-71
[DOI] 10.1002/phar.1388.
[PMID] 24420746.
2014
Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
25(6):1677-84
[DOI] 10.1007/s00198-014-2662-0.
[PMID] 24833176.
2014
Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.
The Journal of antimicrobial chemotherapy.
69(4):1079-85
[DOI] 10.1093/jac/dkt483.
[PMID] 24343893.
2014
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Antimicrobial agents and chemotherapy.
58(2):782-8
[DOI] 10.1128/AAC.01549-13.
[PMID] 24247125.
2014
Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.
Antimicrobial agents and chemotherapy.
58(8):4904-10
[DOI] 10.1128/AAC.01730-13.
[PMID] 24841270.
2014
Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Journal of the Pediatric Infectious Diseases Society.
3(2):132-45
[DOI] 10.1093/jpids/pit077.
[PMID] 26625366.
2014
The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus).
Journal of veterinary pharmacology and therapeutics.
37(5):472-9
[DOI] 10.1111/jvp.12119.
[PMID] 24684601.
2014
Therapeutic drug monitoring in the treatment of tuberculosis: an update.
Drugs.
74(8):839-54
[DOI] 10.1007/s40265-014-0222-8.
[PMID] 24846578.
2013
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
American journal of respiratory and critical care medicine.
188(1):97-102
[DOI] 10.1164/rccm.201212-2328OC.
[PMID] 23593945.
2013
Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.
Pharmacotherapy.
33(1):e1-8
[DOI] 10.1002/phar.1172.
[PMID] 23307552.
2013
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Antimicrobial agents and chemotherapy.
57(8):3910-6
[DOI] 10.1128/AAC.00761-13.
[PMID] 23733473.
2013
Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
Antimicrobial agents and chemotherapy.
57(3):1535-7
[DOI] 10.1128/AAC.01933-12.
[PMID] 23295923.
2013
Reply to “Contradictory results with high-dosage rifamycin in mice and humans”.
Antimicrobial agents and chemotherapy.
57(2):1104-5
[DOI] 10.1128/AAC.02216-12.
[PMID] 23341430.
2013
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
The European respiratory journal.
42(6):1449-53
[DOI] 10.1183/09031936.00073213.
[PMID] 24293417.
2012
Antituberculosis therapy for 2012 and beyond.
Expert opinion on pharmacotherapy.
13(4):511-26
[DOI] 10.1517/14656566.2012.657176.
[PMID] 22332895.
2012
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Antimicrobial agents and chemotherapy.
56(8):4331-40
[DOI] 10.1128/AAC.00912-12.
[PMID] 22664964.
2012
Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
55(2):178-9
[DOI] 10.1093/cid/cis366.
[PMID] 22467672.
2012
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
Antimicrobial agents and chemotherapy.
56(7):3712-9
[DOI] 10.1128/AAC.05453-11.
[PMID] 22526313.
2012
Paediatric use of second-line anti-tuberculosis agents: a review.
Tuberculosis (Edinburgh, Scotland).
92(1):9-17
[DOI] 10.1016/j.tube.2011.11.001.
[PMID] 22118883.
2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
The Journal of antimicrobial chemotherapy.
67(9):2182-90
[DOI] 10.1093/jac/dks201.
[PMID] 22685161.
2012
Pharmacokinetic mismatch of tuberculosis drugs.
Antimicrobial agents and chemotherapy.
56(3)
[DOI] 10.1128/AAC.06303-11.
[PMID] 22337897.
2012
Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.
The Annals of pharmacotherapy.
46(9)
[DOI] 10.1345/aph.1Q456.
[PMID] 22872751.
2012
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Pharmaceutical research.
29(4):972-82
[DOI] 10.1007/s11095-011-0637-9.
[PMID] 22161308.
2012
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Antimicrobial agents and chemotherapy.
56(7):3726-31
[DOI] 10.1128/AAC.00500-12.
[PMID] 22547623.
2012
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Antimicrobial agents and chemotherapy.
56(6):3114-20
[DOI] 10.1128/AAC.00384-12.
[PMID] 22470112.
2012
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
American journal of respiratory and critical care medicine.
186(6):559-65
[DOI] 10.1164/rccm.201204-0682OC.
[PMID] 22744719.
2012
Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritis.
Arthritis and rheumatism.
64(12):3926-35
[DOI] 10.1002/art.37687.
[PMID] 23135697.
2012
Vitamin D, Race, and Knee Osteoarthritic Pain
Gerontologist.
52
2011
Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.
Antimicrobial agents and chemotherapy.
55(4):1781-3
[DOI] 10.1128/AAC.01514-10.
[PMID] 21282421.
2011
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
Antimicrobial agents and chemotherapy.
55(3):1237-47
[DOI] 10.1128/AAC.00595-10.
[PMID] 21135176.
2011
PA-824 exhibits time-dependent activity in a murine model of tuberculosis.
Antimicrobial agents and chemotherapy.
55(1):239-45
[DOI] 10.1128/AAC.00849-10.
[PMID] 20937781.
2011
Pharmacometrics in dose finding or dose optimization of anti-retroviral and anti-tubercular drugs.
Infectious disorders drug targets.
11(2):157-66
[PMID] 21406049.
2011
Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment.
Current pharmaceutical design.
17(27):2889-99
[PMID] 21834766.
2011
Secular trend of adhesive capsulitis.
Arthritis care & research.
63(11):1571-5
[DOI] 10.1002/acr.20590.
[PMID] 22034118.
2011
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Antimicrobial agents and chemotherapy.
55(12):5485-92
[DOI] 10.1128/AAC.05293-11.
[PMID] 21930883.
2011
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
American journal of respiratory and critical care medicine.
183(9):1254-61
[DOI] 10.1164/rccm.201012-1949OC.
[PMID] 21330452.
2010
Aminoglycoside Use in Intensive Care Units and Aminoglycoside Nephrotoxicity
.
54:2750-2751
2010
Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 2.
Antimicrobial agents and chemotherapy.
54(6):2750-1; author reply 2752
[PMID] 20480959.
2010
Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis.
The Annals of pharmacotherapy.
44(7-8):1346-7
[DOI] 10.1345/aph.1P100.
[PMID] 20551298.
2010
Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig.
The Journal of antimicrobial chemotherapy.
65(4):729-34
[DOI] 10.1093/jac/dkq007.
[PMID] 20123722.
2010
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Antimicrobial agents and chemotherapy.
54(10):4192-200
[DOI] 10.1128/AAC.00353-10.
[PMID] 20660695.
2010
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
HIV medicine.
11(3):193-9
[DOI] 10.1111/j.1468-1293.2009.00765.x.
[PMID] 19863619.
2010
The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.
The Journal of antimicrobial chemotherapy.
65(10):2172-5
[DOI] 10.1093/jac/dkq277.
[PMID] 20693172.
2009
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
The Journal of infectious diseases.
200(7):1136-43
[DOI] 10.1086/605605.
[PMID] 19686043.
2009
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
Antimicrobial agents and chemotherapy.
53(4):1338-43
[DOI] 10.1128/AAC.01389-08.
[PMID] 19139288.
2009
Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.
Pharmaceutical research.
26(8):1847-55
[DOI] 10.1007/s11095-009-9894-2.
[PMID] 19407933.
2009
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
13(3):210-7
[PMID] 20191199.
2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
48(12):1685-94
[DOI] 10.1086/599040.
[PMID] 19432554.
2009
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.
Infectious diseases in obstetrics and gynecology.
2009
[DOI] 10.1155/2009/621780.
[PMID] 20130816.
2009
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Antimicrobial agents and chemotherapy.
53(10):4178-84
[DOI] 10.1128/AAC.00830-09.
[PMID] 19620331.
2009
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
49(9):1305-11
[DOI] 10.1086/606056.
[PMID] 19807276.
2009
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.
Antimicrobial agents and chemotherapy.
53(9):3981-4
[DOI] 10.1128/AAC.01378-08.
[PMID] 19564361.
2009
Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.
The American journal of tropical medicine and hygiene.
81(2):322-9
[PMID] 19635892.
2009
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Pharmacotherapy.
29(5):503-10
[DOI] 10.1592/phco.29.5.503.
[PMID] 19397460.
2009
Tuberculosis pharmacotherapy: strategies to optimize patient care.
Expert opinion on pharmacotherapy.
10(3):381-401
[DOI] 10.1517/14656560802694564.
[PMID] 19191677.
2008
Concomitant use of voriconazole and rifabutin in a patient with multiple infections.
Pharmacotherapy.
28(8):1076-80
[DOI] 10.1592/phco.28.8.1076.
[PMID] 18657024.
2008
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.
American journal of respiratory and critical care medicine.
178(11):1180-5
[DOI] 10.1164/rccm.200806-892OC.
[PMID] 18787216.
2008
Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).
Journal of the American Association for Laboratory Animal Science : JAALAS.
47(4):41-5
[PMID] 18702450.
2008
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
Antimicrobial agents and chemotherapy.
52(11):4137-40
[DOI] 10.1128/AAC.00196-08.
[PMID] 18694944.
2008
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Antimicrobial agents and chemotherapy.
52(3):852-7
[PMID] 18070980.
2008
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
Antimicrobial agents and chemotherapy.
52(11):4037-42
[DOI] 10.1128/AAC.00554-08.
[PMID] 18765687.
2008
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Bioorganic & medicinal chemistry letters.
18(10):3029-33
[DOI] 10.1016/j.bmcl.2008.04.038.
[PMID] 18457948.
2008
Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs.
Canadian respiratory journal.
15(5):241-3
[PMID] 18716684.
2007
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Pharmacotherapy.
27(6):793-800
[PMID] 17542762.
2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
PLoS medicine.
4(12)
[PMID] 18092886.
2007
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
Antimicrobial agents and chemotherapy.
51(8):2861-6
[PMID] 17517835.
2007
Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
The Journal of antimicrobial chemotherapy.
60(4):819-23
[PMID] 17673476.
2007
Stability of antituberculosis drugs mixed in food.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
45(4)
[PMID] 17638210.
2007
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
HIV medicine.
8(7):457-64
[PMID] 17760738.
2006
Amikacin dosing and monitoring in spinal cord injury patients: variation in clinical practice between spinal injury units and differences in experts’ recommendations.
TheScientificWorldJournal.
6:187-99
[PMID] 16493523.
2006
An official ATS statement: hepatotoxicity of antituberculosis therapy.
American journal of respiratory and critical care medicine.
174(8):935-52
[PMID] 17021358.
2006
Clearance of linezolid via continuous venovenous hemodiafiltration.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
47(6):e83-6
[PMID] 16731287.
2006
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Antimicrobial agents and chemotherapy.
50(8):2621-5
[PMID] 16870750.
2006
Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
Journal of veterinary pharmacology and therapeutics.
29(6):581-5
[PMID] 17083464.
2006
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
10(6):605-12
[PMID] 16776446.
2006
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
10(6):374-9
[PMID] 17420908.
2006
Mycobacterium avium in pygmy rabbits (Brachylagus idahoensis): 28 cases.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.
37(4):498-512
[PMID] 17315435.
2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
American journal of respiratory and critical care medicine.
174(1):94-101
[PMID] 16574936.
2005
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
40(10):1481-91
[PMID] 15844071.
2005
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
41(9):1343-9
[PMID] 16206114.
2005
Human vitreous distribution of linezolid after a single oral dose.
Retina (Philadelphia, Pa.).
25(5):619-24
[PMID] 16077360.
2005
Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
The Annals of pharmacotherapy.
39(3):427-32
[PMID] 15701775.
2005
Pharmacokinetics of ethambutol (EMB) in elephants.
Journal of veterinary pharmacology and therapeutics.
28(3):321-3
[PMID] 15953208.
2005
Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).
Journal of veterinary pharmacology and therapeutics.
28(1):21-7
[PMID] 15720511.
2005
Population pharmacokinetics of pyrazinamide in elephants.
Journal of veterinary pharmacology and therapeutics.
28(5):403-9
[PMID] 16207301.
2005
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
41(4):461-9
[PMID] 16028152.
2005
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
41(11):1638-47
[PMID] 16267738.
2005
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
American journal of respiratory and critical care medicine.
172(11):1457-62
[PMID] 16141439.
2004
Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
38(11):1538-44
[PMID] 15156439.
2004
Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Tuberculosis (Edinburgh, Scotland).
84(6):365-73
[PMID] 15525560.
2004
Pharmacokinetics of ethambutol in children and adults with tuberculosis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
8(11):1360-7
[PMID] 15581206.
2004
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
American journal of respiratory and critical care medicine.
169(11):1191-7
[PMID] 14962821.
2004
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
38(4):556-64
[PMID] 14765350.
2004
Use of therapeutic drug monitoring in tuberculosis patients.
Chest.
126(6):1722-4
[PMID] 15596662.
2003
Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Antimicrobial agents and chemotherapy.
47(1):398-9
[PMID] 12499223.
2003
Direct lung delivery of para-aminosalicylic acid by aerosol particles.
Tuberculosis (Edinburgh, Scotland).
83(6):379-85
[PMID] 14623169.
2003
Linezolid clearance during continuous venovenous hemodiafiltration: a case report.
Pharmacotherapy.
23(8):1071-5
[PMID] 12921253.
2003
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
American journal of respiratory and critical care medicine.
167(10):1341-7
[PMID] 12531776.
2003
Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis.
Pharmacotherapy.
23(10):1322-6
[PMID] 14594349.
2003
Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
37(4):607-8
[PMID] 12905149.
2003
What is the ‘right’ dose of rifampin?
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
7(1):3-5
[PMID] 12701829.
2002
Linezolid stability in peritoneal dialysis solutions.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
22(3):419-22
[PMID] 12227405.
2002
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Chest.
121(1):281-4
[PMID] 11796464.
2001
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
Clinical pharmacokinetics.
40(5):327-41
[PMID] 11432536.
2001
Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Pharmacotherapy.
21(8):891-7
[PMID] 11718495.
2001
Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.
Antimicrobial agents and chemotherapy.
45(3):810-4
[PMID] 11181366.
2001
Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.
The Annals of pharmacotherapy.
35(11):1332-8
[PMID] 11724078.
2001
Pharmacological issues in the treatment of tuberculosis.
Annals of the New York Academy of Sciences.
953:157-64
[PMID] 11795409.
2001
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.
Pharmacotherapy.
21(9):1037-45
[PMID] 11560193.
2001
Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review.
Scandinavian journal of infectious diseases.
33(5):375-9
[PMID] 11440224.
2001
Tuberculosis drug serum levels.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
33(4):584-5
[PMID] 11462203.
2000
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
The Journal of antimicrobial chemotherapy.
45:9-17
[PMID] 10719007.
1999
AIDS and TB drug absorption.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
3(12):1143-4
[PMID] 10599022.
1999
Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii).
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.
30(1):36-43
[PMID] 10367642.
1999
Clofazimine crystals in the cytoplasm of pulmonary macrophages.
The Annals of pharmacotherapy.
33(2)
[PMID] 10084424.
1999
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers.
Antimicrobial agents and chemotherapy.
43(5):1152-5
[PMID] 10223928.
1999
Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications.
The Annals of pharmacotherapy.
33(11):1184-8
[PMID] 10573317.
1999
Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
American journal of respiratory and critical care medicine.
159(3):932-4
[PMID] 10051275.
1999
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids.
Antimicrobial agents and chemotherapy.
43(3):568-72
[PMID] 10049268.
1999
Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
3(8):703-10
[PMID] 10460103.
1999
Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.
Chest.
115(1):12-8
[PMID] 9925057.
1999
Potential interaction between itraconazole and clarithromycin.
Pharmacotherapy.
19(12):1439-44
[PMID] 10600094.
1999
The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Chest.
116(4):984-90
[PMID] 10531163.
1999
The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
American journal of respiratory and critical care medicine.
159(5 Pt 1):1580-4
[PMID] 10228130.
1999
Therapeutic drug monitoring in antituberculosis chemotherapy.
Therapeutic drug monitoring.
21(4):426-7
[PMID] 10442697.
1999
Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease.
The European respiratory journal.
14(2):347-51
[PMID] 10515412.
1999
Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
28(3):419-29; quiz 430
[PMID] 10194057.
1998
Effect of grapefruit juice on clarithromycin pharmacokinetics.
Antimicrobial agents and chemotherapy.
42(4):927-9
[PMID] 9559810.
1998
Levofloxacin for drug-resistant Mycobacterium tuberculosis.
The Annals of pharmacotherapy.
32(2):268-9
[PMID] 9496417.
1998
Oral cimetidine prolongs clarithromycin absorption.
Antimicrobial agents and chemotherapy.
42(7):1578-80
[PMID] 9660986.
1998
Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids.
Pharmacotherapy.
18(6):1205-11
[PMID] 9855317.
1998
Rifampin stability.
Therapeutic drug monitoring.
20(4):450-1
[PMID] 9712473.
1998
Serum concentrations of the antimycobacterial drugs.
Chest.
113(5):1154-5
[PMID] 9596284.
1997
Advice on treatment of drug-resistant tuberculosis.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
54(6):700-1
[PMID] 9075505.
1997
Advice on treatment of Mycobacterium avium complex infection.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
54(10):1208-9
[PMID] 9161632.
1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.
American journal of respiratory and critical care medicine.
156(3 Pt 1):918-23
[PMID] 9310014.
1997
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.
Clinical pharmacokinetics.
32(2):132-44
[PMID] 9068928.
1997
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
Antimicrobial agents and chemotherapy.
41(12):2670-9
[PMID] 9420037.
1997
The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.
Drugs.
54(1):69-80
[PMID] 9211081.
1997
Using therapeutic drug monitoring to dose the antimycobacterial drugs.
Clinics in chest medicine.
18(1):79-87
[PMID] 9098612.
1996
Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
22(5)
[PMID] 8722972.
1996
Low antituberculosis drug concentrations in patients with AIDS.
The Annals of pharmacotherapy.
30(9):919-25
[PMID] 8876848.
1996
Pharmacokinetic evaluation of thiacetazone.
Pharmacotherapy.
16(5):735-41
[PMID] 8888068.
1996
Quinolones and tuberculosis.
The Annals of pharmacotherapy.
30(9):1034-5
[PMID] 8876870.
1996
Therapeutic drug monitoring of the antimycobacterial drugs.
Clinics in laboratory medicine.
16(3):717-29
[PMID] 8866188.
1995
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.
Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
76(5):463-7
[PMID] 7496011.
1995
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
American journal of respiratory and critical care medicine.
151(6):2006-9
[PMID] 7767552.
1995
Recent advances: antiinfectives.
The Annals of pharmacotherapy.
29(10):1035-40
[PMID] 8845542.
1995
Tuberculosis and multi-drug resistant tuberculosis in children.
Pediatric nursing.
21(6):566-72
[PMID] 8700614.
1995
Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration.
Pharmacotherapy.
15(2):236-45
[PMID] 7624271.
1994
Clarification: controversies in the management of Mycobacterium avium complex infection in AIDS.
The Annals of pharmacotherapy.
28(6)
[PMID] 7919579.
1994
Infection caused by Mycobacterium tuberculosis.
The Annals of pharmacotherapy.
28(1):72-84
[PMID] 8123968.
1994
Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug.
Pharmacotherapy.
14(4):415-23
[PMID] 7937278.
1994
Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Pharmacotherapy.
14(1):40-6
[PMID] 8159600.
1993
Comment: intravenous streptomycin.
The Annals of pharmacotherapy.
27(12):1546-7
[PMID] 7508298.
1993
Controversies in the management of Mycobacterium avium complex infection in AIDS patients.
The Annals of pharmacotherapy.
27(7-8):928-37
[PMID] 8364280.
1993
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
The Journal of infectious diseases.
168(6):1559-62
[PMID] 8245546.
1993
Malabsorption of antimycobacterial medications.
The New England journal of medicine.
329(15):1122-3
[PMID] 8371737.
1993
Pharmacology of the antimycobacterial drugs.
The Medical clinics of North America.
77(6):1253-62
[PMID] 8231410.
1992
Malabsorption of antituberculosis medications by a patient with AIDS.
The New England journal of medicine.
327(25):1817-8
[PMID] 1435941.
1992
Shortages of antimycobacterial drugs.
The New England journal of medicine.
326(10)
[PMID] 1736124.
1991
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.
Antimicrobial agents and chemotherapy.
35(10):1953-9
[PMID] 1759813.
1991
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.
Antimicrobial agents and chemotherapy.
35(10):1947-52
[PMID] 1759812.
1991
Dosage of antimycobacterial agents.
Clinical pharmacy.
10(9):664-5
[PMID] 1914427.
1991
Improved high-performance liquid chromatographic assay for the determination of ethionamide in serum.
Journal of chromatography.
563(2):472-5
[PMID] 2056012.
1991
Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses.
Antimicrobial agents and chemotherapy.
35(6):1191-5
[PMID] 1929261.
1991
Pharmacokinetic evaluation of ethionamide suppositories.
Pharmacotherapy.
11(5):359-63
[PMID] 1745621.
1990
Fighting tuberculosis with old weapons.
DICP : the annals of pharmacotherapy.
24(9):883-4
[PMID] 2260350.
1989
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Archives of internal medicine.
149(10):2269-73
[PMID] 2508586.
1988
Storing extra calibration curves in the TDx assay system.
Clinical pharmacy.
7(11):792-3
[PMID] 3197380.
1987
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
The American journal of medicine.
82(4A):352-6
[PMID] 3555060.
Use of Therapeutic Drug Monitoring to Characterize Cefepime-Induced Neurotoxicity
.
[DOI] 10.1101/2020.08.13.250456.
Grants
Sep 2021
– Feb 2023
Beta-lactam continuous vs intermittent infusion and associated bacterial resistance and therapy outcomes in critically ill patients with severe pneumonia
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Jul 2021
ACTIVE
Cefepime pharmacokinetics, protein binding, and precision dosing in burn ICU patients
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
May 2021
ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2021
ACTIVE
Early intervention augmenting GABA-ergic pathways: The VIGAB-STAT – VIGABatrin in post-anoxic STATus epilepticus
Role: Co-Investigator
Funding: AMER HEART ASSOCIATION
Dec 2020
ACTIVE
Pharmacokinetics and Pharmacodynamics of Dolutegravir in Children Weighing =20 Kg Living with HIV with and without TB Coinfection
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Sep 2020
ACTIVE
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
Role: Principal Investigator
Funding: UNIV OF VIRGINIA
via NATL INST OF HLTH NIAID
Nov 2019
– Feb 2021
LegoChem Data Analysis – Task Order #1
Role: Principal Investigator
Funding: LEGOCHEM BIOSCIENCES
May 2019
– Aug 2022
Development of Gleevec for TB and TB/HIV
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Apr 2019
– Apr 2020
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
Role: Principal Investigator
Funding: RUTGERS STATE UNIV
via NATL INST OF HLTH NIAID
Feb 2019
– Jan 2021
Diagnostics and Pharmacotherapy for Severe Forms of TB
Role: Principal Investigator
Funding: UNIV OF VIRGINIA
via NATL INST OF HLTH NIAID
Sep 2018
ACTIVE
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Role: Co-Investigator
Funding: NATL INST OF HLTH NICHD
Jul 2018
– Jun 2021
An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Feb 2018
– Jan 2019
Diagnostics and Pharmacotherapy for Severe Forms of TB
Role: Principal Investigator
Funding: UNIV OF VIRGINIA
via NATL INST OF HLTH NIAID
Oct 2017
– Dec 2018
Screening and Treatment of Children and Adults Exposed at Home to Drug-Resistant Tuberculosis
Role: Principal Investigator
Funding: HARVARD MEDICAL SCHOOL
Aug 2017
ACTIVE
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)
Role: Principal Investigator
Funding: BOSTON UNIV
via NATL INST OF HLTH NIAID
Aug 2016
– Jul 2022
Optimizing combination therapy for accelerate clinical cure of tuberculosis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2016
– May 2017
Pharmacokinetics of second-line anti-tuberculosis drugs among patients with multidrug-resistant tuberculosis
Role: Principal Investigator
Funding: INTL SCIENCE AND TECHNOLOGY CENTER
Jun 2016
– Aug 2018
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Role: Co-Investigator
Funding: NATL INST OF HLTH NICHD
Feb 2016
– Jan 2018
A Clinical Pharmacology Study of a Novel Drug Regimen for Pre XDR and XDR Tuberculosis
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Feb 2016
– Jan 2018
MD-INMD Diagnostics and Pharmacotherapy for Service Year 2
Role: Principal Investigator
Funding: UNIV OF VIRGINIA
via NATL INST OF HLTH NIAID
Sep 2015
– Mar 2017
task A73: Combination drug testing for new TB regimens
Role: Principal Investigator
Funding: TEXAS A&M RES FOU
via NATL INST OF HLTH
Aug 2014
– Dec 2018
Rifampin and Lopinavir Study
Role: Principal Investigator
Funding: UNIV OF MIAMI
Mar 2014
– Jun 2018
Pharmacokinetics and Pharmacodynamics of Tuberculosis Drugs in Patients with Active Disease
Role: Principal Investigator
Funding: CRITICAL PATH INSTITUTE
via GATES FOU, BILL & MELINDA
Feb 2014
– Feb 2017
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated with Efavirenz Therapy
Role: Principal Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL
Feb 2014
– Jul 2017
Immune Activation and Drug Absorption in HIV-Infected Patients
Role: Principal Investigator
Funding: DREXEL UNIVERSITY
via JANSSEN SCIENTIFIC AFFAIRS
Aug 2013
– Jul 2018
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
Role: Principal Investigator
Funding: BOSTON UNIV
via NATL INST OF HLTH NIAID
Jul 2013
– Jun 2016
Intracavitary Drug Levels in Patients with Drug Resistant Tuberculosis
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH
Jun 2009
– Nov 2021
Moxifloxain PK in Bile.
Role: Principal Investigator
Funding: MULTIPLE SPONSORS
Education
Pharm.D.
1986
·
Philadelphia College of Pharmacy and Science
B.S.
1981
·
University of Connecticut
Contact Details
Phones:
- Business:
- (352) 273-6266
Emails:
- Business:
- peloquin@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD RM P4 33
GAINESVILLE FL 32610